• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Inflow, a platform for managing ADHD through cognitive behavioral therapy, raises $11M
Inflow, a company developing a platform to manage ADHD using cognitive behavioural therapy (CBT) techniques, has raised $11 million in a Series A round of funding. ADHD, or “attention deficit hyperactivity disorder,” is a condition impacting as much as 10% of the global population. Symptoms vary,…#sebisaacs #sachsandco #paulsawers #inflowsseries #brili #octopusventures #inflow #trialsinflow #leviepstein #cerebral
Source: Reuters: Health - January 11, 2023 Category: Consumer Health News Source Type: news

Virtual #CochraneSantiago - Meet our content creators!
Cochrane ’s first virtual Colloquium is happening 2-6 December, 2019. Cochrane ’s Colloquium is an annual, global health event based on promoting the most prestigious evidence in the world and where hundreds of international researchers, opinion leaders, health experts and patients join together for open, scientific debate promoting the use of evidence in health. Through act ivities and presentations, we will be exploring this year ' s theme of “Embracing diversity”.Meet our content creator volunteers who will be helping to share the work of Cochrane and our virtual#CochraneSantiagomaterials and discussion to their...
Source: Cochrane News and Events - October 7, 2019 Category: Information Technology Authors: Muriah Umoquit Source Type: news

#CochraneSantiago - Meet our content creators!
Cochrane Chile is hostingCochrane ’s Colloquium in Santiago, October 22-25, 2019. Cochrane ’s Colloquium is an annual, global health event based on promoting the most prestigious evidence in the world and where hundreds of international researchers, opinion leaders, health experts and patients join together for open, scientific debate promoting the use of evidence in health. Through tal ks, workshops and other activities and presentations, we will be exploring this year ' s theme of “Embracing diversity”.Meet our content creator volunteers who will be helping to share the work of Cochrane and extend our annual scie...
Source: Cochrane News and Events - October 7, 2019 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Cognitive-behavioural therapy for attention deficit hyperactivity disorder (ADHD) in adults
The Cochrane Developmental, Psychosocial and Learning Problems Group covers a wide range of topics relevant to the mental health of both adults and children in the more than 140 Cochrane Reviews it has produced to date. In March 2018, it added to these with a new review of cognitive-behavioural interventions for attention deficit hyperactivity disorder in adults. We asked one of the authors, Pablo Lopez from INECO Foundation and Favaloro University in Buenos Aires, Argentina, to tell us more in this podcast.
Source: Podcasts from The Cochrane Library - April 10, 2018 Category: General Medicine Authors: Cochrane Source Type: podcasts

Group cogntive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder
Persistence of attention-deficit hyperactivity disorder (ADHD) into adolescence is associated with a broad range of negative outcomes1 and high rates of treatment discontinuation.2 While clinical guidelines recommend non-pharmacological therapies as the first-line treatment for adolescents with ADHD3 the evidence to support this recommendation is sparse and generally not convincing. More specifically there is inadequate evidence to properly support the efficacy of either group or individual cognitive-behavioural therapy (CBT) for this patient group.4
Source: Current Awareness Service for Health (CASH) - March 2, 2016 Category: Consumer Health News Source Type: news

Experts call for more research into ADHD drug Ritalin
ConclusionThis is a well-conducted systematic review that aimed to assess the beneficial and harmful effects of methylphenidate (Ritalin being the most commonly known brand name) for children and adolescents with ADHD.The review found that methylphenidate was associated with a slight improvement in the symptoms of ADHD, compared to placebo or no treatment – just on the borderline of what would be considered clinically meaningful. However, the researchers state this improvement should be weighed up against the increased risk of adverse events, such as sleeping problems and decreased appetite. The review identified a large...
Source: NHS News Feed - November 27, 2015 Category: Consumer Health News Tags: Mental health Medication Pregnancy/child Medical practice Source Type: news

Five 'mental disorders' may have genetic links
Conclusion This study suggests that autism, ADHD, clinical depression, bipolar disorder and schizophrenia may have common genetic risk factors. The five conditions examined in this study were selected on the basis of the availability of a large genetic data set. It is unclear at this stage whether other relatively common mental health conditions (such as anxiety disorder or obsessive compulsive disorder) are also affected by these genetic variations, or whether there is overlap with other conditions. Perhaps most importantly, these variations cannot on their own predict or explain the development of autism, ADHD, depressi...
Source: NHS News Feed - February 28, 2013 Category: Consumer Health News Tags: Genetics/stem cells Mental health Source Type: news